AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03453957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professional development program
Description: Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
Study NCT03934918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Patients for IOL are sent home after placement of intracervical balloon
Study NCT03059537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral chenodeoxycholic acid stimulation
Description: oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
Study NCT02830074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best practices PAP + patient Education +ongoing Support and Training
Description: This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training
Study NCT02830074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: This program includes non-directive sleep education plus standard treatment of SDB.
Study NCT01834664 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: stem cell (MNCs )
Description: Intra thecal transplantation of autologous stem cell \[MNCs \]Per dose at the interval
Study NCT05514613 — intervention group
Intervention type: OTHER
Intervention: retrospektif study; The effect of tracheostomy tecnique method on complications
Description: retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques
Study NCT03778060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala TWO stimulator
Description: Treatment intervention will consist of subjects undergoing 40 minute sessions of transcutaneous stimulation with the Cala TWO stimulator twice daily for 3 months to reduce hand tremors prior to their undergoing deep brain stimulation 'surgery for treatment of essential tremor at Mayo Clinic.
Study NCT03231397 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Assess AAA rupture risk by PET-CTA scans
Description: Assess AAA rupture risk by PET-CTA scans
Study NCT03231397 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F-fludeoxyglucose (FDG)
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
Study NCT03231397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 11C-PBR28
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
Study NCT02758288 — intervention group
Intervention type: OTHER
Intervention: New Protocol - BK viremia or BK virus nephropathy
Description: Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
Study NCT02758288 — intervention group
Intervention type: OTHER
Intervention: Standard Protocol - BK viremia or BK virus nephropathy
Description: Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
Study NCT01641471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMPI Select TENS
Description: The unit is capable of 0-60 milliamps of output current.
Study NCT01641471 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EMPI Select TENS
Description: The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
Study NCT01183507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NIA intervention
Description: The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.
Study NCT01183507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSE
Description: The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
Study NCT03993977 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rotational thromboelastometry
Description: ROTEM-guided protocol of hemostatic resuscitation
Study NCT03993977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Clinical judgement and conventional coagulation tests
Study NCT02685332 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Stereotactic Body Partial Breast irradiation Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1. 1 26.5~2. 1 30
Study NCT04099238 — intervention group
Intervention type: DRUG
Intervention: Oral anticoagulant
Description: Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
Study NCT04929977 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device with smart mobile phone
Description: The wearable device will act as a sensor designed to identify critical parameters such as Kangaroo Mother Care adherence and temperature of the infant 24/7 and of the mother-infant pairs during these sessions.
Study NCT01383408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhalation analysis of breath sample
Description: study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
Study NCT01383408 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exhalation analysis of breath sample
Description: study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
Study NCT00765817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, twice a day
Study NCT00765817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, twice a day, 10mcg
Study NCT00528918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glulisine (Apidra)
Description: An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
Study NCT03243123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic passive mobilization
Description: The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.
Study NCT02482545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal replacement
Study NCT00812942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy
Description: colonoscopy screening
Study NCT00812942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: faecal test
Description: faecal occult blood test for screening
Study NCT02085928 — intervention group
Intervention type: OTHER
Intervention: Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching
Description: * The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).~* The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.~* The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon.
Study NCT03479476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Medication
Description: Placebo liquid or capsules given in parallel to active medication.
Study NCT03479476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Active medication.
Study NCT02552017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff Vision
Description: Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
Study NCT01986088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT01986088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Description: 40mg oral
Study NCT01986088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Description: 80mg oral
Study NCT01986088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Description: 50mg oral
Study NCT01986088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Description: 100mg oral
Study NCT00527787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400 (VIMOVO)
Description: PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
Study NCT00527787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen (500 mg) dosed twice daily (bid) orally
Study NCT02700542 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Integrated Pest Management
Description: One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
Study NCT02700542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Pest Management
Description: One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
Study NCT02986308 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02878694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myoblast autologous graft
Description: 30 million autologous myoblasts in 6 intramuscular injections No treatment in the second eye
Study NCT03750929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined acute physical exercises (strength and aerobic)
Description: Patients will be submmitted to combined acute physical exercises (strength and aerobic)
Study NCT03973268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 1, 2, 3 device interventions
Description: MagPro 100 TMS Therapy System
Study NCT03973268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 2 Interventions
Description: Placebo
Study NCT03973268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1, 2, 3 drug Interventions
Description: Ketamine
Study NCT03973268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 and 2 Interventions
Description: Perampanel
Study NCT04621253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novalgin
Description: Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake
Study NCT04621253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Novalgin
Description: Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake
Study NCT03040934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Firehawk sirolimus target eluting coronary stent system
Description: 98 subjects will be enrolled to receive a test device of Firehawk sirolimus target eluting coronary stent system
Study NCT03040934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE Everolimus-Eluting Coronary Stent System
Description: 98 subjects will be enrolled to receive a control device of XIENCE Everolimus-Eluting Coronary Stent System
Study NCT00903500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily physical activity, pedometer and counseling
Description: Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
Study NCT03916796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: -The exercise part will consist of an evaluation and treatment as prescribed by a physical therapist including aerobic \& dynamic stretching warm-up, strength training, balance training, and flexibility training. Will also include a home exercise program (HEP). Physical therapists will have specialized training in cancer rehabilitation obtained through the ReVital certification process.
Study NCT03916796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery after surgery
Description: -The protocols include instructions for patient care from the time of pre-surgical admission to discharge, including directives regarding diet, labs, IV fluids, pain management, prophylactic medications, management of indwelling catheters and drains, and activity.
Study NCT03916796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological screening with counselling services as needed
Description: -The psychological screening will be completed by the Radiation Oncology nurse at the consult visit
Study NCT03916796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling Services
Description: -Patients will have a baseline nutrition counseling visit with a Registered Dietician. This may include a nutrition assessment and nutrition counseling to set priorities, establish goals, and create an individualized plan
Study NCT01603888 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01795599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifegyne ®
Study NCT01795599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifegyne ®
Study NCT01795599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gymiso®
Study NCT01795599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gymiso®
Study NCT03487198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole 2-3mg/day
Study NCT03487198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2-3 mg/day
Study NCT02909465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Using Midazolam as a premedication for reducing ketamine-induced agitation
Study NCT02909465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Using Haloperidol as a premedication for reducing ketamine-induced agitation
Study NCT02909465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: distilled water
Study NCT02909465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: distilled water
Study NCT02498977 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker
Description: Real time polymerase chain reaction (PCR) gene expression measurement
Study NCT02498977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine
Description: Immunosuppression drugs as per protocol
Study NCT01913522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation
Study NCT01913522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Vein Isolation
Study NCT03300362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Description: Seasonal influenza vaccine
Study NCT03300362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: Seasonal influenza vaccine
Study NCT03300362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Trial vaccine
Study NCT03300362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Saline placebo
Study NCT00664365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK958108
Description: GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
Study NCT00664365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
Study NCT02909465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is routinely used for all procedural sedation in the patients.
Study NCT02909465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine is routinely used for all procedural sedation in the patients.
Study NCT02238249 — intervention group
Intervention type: DRUG
Intervention: Alesion®
Description: Dry Syrup
Study NCT04663165 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periodontal surgery
Description: Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing. Elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device. Flap closure with non-resorbable sutures.
Study NCT04663165 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regenerative periodontal surgery
Description: Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing combined with vertical bone defect of 4mm or more. After elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device, adjunctive treatment with EDTA gel applied to root surface for two minutes, followed by rinsing with saline solution. Finally, application of enamel matrix derivative on a blood free root surface, followed by flap closure with non-resorbable sutures.
Study NCT00199849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Plasmid DNA Cancer Vaccine
Description: NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.
Study NCT01442649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
Study NCT01442649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
Study NCT01862497 — intervention group
Intervention type: DRUG
Intervention: Carvedilol vs. Prazosin
Study NCT00804505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens
Description: Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
Study NCT00804505 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens
Description: Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
Study NCT01442649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoro-uracil
Description: 400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
Study NCT01442649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity